血栓通治疗冠心病有效性和安全性的Meta分析

目的综合评价血栓通治疗冠心病的有效性和安全性,为临床治疗决策提供科学依据。方法利用计算机检索文献,并进行筛选,在对纳入文献进行方法学质量评价后,应用RevMan5.0软件,采用固定效应模型或随机效应模型对纳入文献进行Meta分析。结果本研究共纳入31篇文献,质量评级均为C级。在心电图总有效方面,血栓通单用VS复方丹参单用、血栓通联用其它药物VS复方丹参联用其它药物、血栓通联用硝酸甘油VS硝酸甘油、血栓通联用其它药物VS其它药物比较,RR及95%CI分别为1.45（1.29～1.62）、1.19（1.01～1.41）、1.22（1.10～1.34）、1.28（1.19～1.38）,差异具有统计学意义。在心绞痛总有效方面,血栓通联用其它药物VS其它药物、血栓通联用硝酸甘油VS硝酸甘油比较,RR及95%CI分别为1.28（1.19～1.38）、1.30（1.15～1.48）,差异具有统计学意义。敏感性分析验证了结果的稳定性。结论血栓通不论是单用还是与其它药物联合应用,在心绞痛和心电图总有效方面均较其它药物优秀。

Meta-Analysis on the Efficacy and Safety of Xueshuantong for Coronary Heart Disease

Objective To evaluate efficacy and safety of Xueshuantong for coronary heart disease,from which to provide scientific proofs for clinical decision making. Methods We firstly retrieved and selected literatures,and the methodological quality evaluation of the included articles was followed.Afterwards, using Cochrane Collaboration＇s software RevMan 5.0, we conducted Meta-analysis with fixed or random effect model. Results A total of thirty one papers were included in the study and the methodological quality was graded to C.When Jt comes to electrocardiogram total response rate, RRs and 95%CI were 1.45 （1.29- 1.62）, 1.19 （1.01 - 1.41 ）, 1.22 （1.10- 1.34）, 1.28 （1.19-1.38）which indicated there were significant differences between Xueshuantong alone and Fufang Danshen alone, Xueshuantong＋other drugs combination and Fufang Danshen＋other drugs combination, Xueshuantong＋Nitroglycerinum combination and Nitroglyceriqum alone, Xueshuantong＋other drugs combination and other drugs. As for angina total response rate, Significance differences were noted between Xueshuantong＋other drugs combination and other drugs, Xueshuantong＋Nitroglycerinum combination and Nitroglycerinum alone where RRs and 95%CI were 1.28 （1.19 - 1.38）, 1.30 （1.15- 1.48）. The sensitivity analysis tested and verified the reliability of the results above. Conclusions The adoption of Xueshuantong for coronary heart disease can improve total response rate.